{
    "name": "vitamin D",
    "comment": "Rx, OTC",
    "other_names": [
        "Drisdol",
        "Calciferol",
        "cholecalciferol",
        "1",
        "25-Dihydroxycholecalciferol",
        "ergocalciferol"
    ],
    "classes": [
        "Vitamins",
        "Fat-Soluble"
    ],
    "source": "https://reference.medscape.com/drug/drisdol-calciferol-vitamind-344417",
    "pregnancy": {
        "common": [
            "Pregnancy category: C (ergocalciferol)",
            "Lactation: Drug is distributed into breast milk; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Drug is distributed into breast milk; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypercalcemia",
                "Hypervitaminosis D",
                "Ergocalciferol (oral): Gastrointestinal (GI), liver, or biliary disease associated with malabsorption of vitamin D analogues",
                "Documented hypersensitivity with drugs that could have allergenic crossreactivity with ergocalceferol"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Ergocalciferol: Use with caution in renal impairment (strong caution), heart disease, kidney stones, arteriosclerosis",
                "Obtain serum calcium twice weekly during titration",
                "Discontinue if patient becomes hypercalcemic",
                "Presence of tartrazine in some products may cause allergic reactions",
                "Vitamin D toxicity may last ≥2 months after therapy is discontinued",
                "Restrict intake in infants with idiopathic hypercalcemia",
                "Concurrent use of cardiac glycosides",
                "Adequate clinical response to vitamin D therapy is dependent on adequate dietary calcium",
                "Maintain normal serum phosphorous concentrations in patients treated for hyperphosphatemia to prevent metastatic calcification",
                "When treating hypoparathyroidism, concomitant treatment with intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may also be required",
                "Adults with a body mass index (BMI) greater than 30 kg/m² are at high risk for vitamin D deficiency due to storage of vitamin D in adipose tissue; doses higher than recommended daily allowance may be required, but must be carefully monitored to avoid toxicity",
                "Metabolism of vitamin D may be altered in patients with chronic kidney disease",
                "In renal impairment, supplementation with ergocalciferol may be necessary; monitor closely",
                "In patients with rickets, the range between therapeutic and toxic doses is narrow in vitamin D–resistant patients; adjust dose based on clinical response to avoid toxicity"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "vitamin D and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "vitamin D, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "vitamin D increases levels of aluminum hydroxide by Other (see comment). Use Caution/Monitor. \nComment: Avoid coadministration. Chronic use of aluminum-containing antacids in conjunction with vitamin D can lead to aluminum retention and possible toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "vitamin D, calcium acetate. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "vitamin D, calcium carbonate. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "vitamin D, calcium chloride. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "vitamin D, calcium citrate. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "vitamin D, calcium gluconate. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine will decrease the level or effect of vitamin D by  Other (see comment). Use Caution/Monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to cholestyramine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colesevelam",
            "description": {
                "common": "colesevelam will decrease the level or effect of vitamin D by  Other (see comment). Use Caution/Monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to colesevelam."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol will decrease the level or effect of vitamin D by  Other (see comment). Use Caution/Monitor. Bile acid sequestrants may decrease the absorption of fat-soluble vitamins. Administer vitamin supplementation at least 4 hours prior to colestipol."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "vitamin D increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D may cause hypercalcemia which may affect the actions of digoxin and/or lead to cardiac arrhythmias."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D supplementation or dosage adjustments may be required in patients who are receiving chronic treatment with anticonvulsants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "vitamin D increases levels of magnesium citrate by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D can increase serum magnesium concentrations, particularly in the presence of renal impairment. The combined use of vitamin D and magnesium-containing products should be avoided, if possible, in patients with chronic renal failure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "vitamin D increases levels of magnesium hydroxide by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D can increase serum magnesium concentrations, particularly in the presence of renal impairment. The combined use of vitamin D and magnesium-containing products should be avoided, if possible, in patients with chronic renal failure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mineral oil",
            "description": {
                "common": "mineral oil will decrease the level or effect of vitamin D by  Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat will decrease the level or effect of vitamin D by  Other (see comment). Use Caution/Monitor. When combination must be used, may consider administering vitamin D at least 2 hours before or after administration of orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D supplementation or dosage adjustments may be required in patients who are receiving chronic treatment with anticonvulsants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D supplementation or dosage adjustments may be required in patients who are receiving chronic treatment with anticonvulsants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Vitamin D supplementation or dosage adjustments may be required in patients who are receiving chronic treatment with anticonvulsants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sucralfate",
            "description": {
                "common": "vitamin D increases levels of sucralfate by Other (see comment). Use Caution/Monitor. \nComment: Avoid coadministration. Vitamin D analogs may increase the absorption of aluminum from sucralfate. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Arrhythmias",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Dry mouth",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hypercalcemia",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Metallic taste",
            "percent": null
        },
        {
            "name": "Muscle or bone pain",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Sluggishness",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}